Related references
Note: Only part of the references are listed.ChemoTherapy aNd chemoradioTherapy for adenocarcinoma of the OESophagus and esophagogastric junction with oligometastases: Protocol of the TNT-OES-1 trial
Charlene J. .van der Zijden et al.
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS (2022)
Signet Ring Cell Histology Confers Worse Overall Survival in Treated Esophageal Adenocarcinoma
Andrew Tang et al.
ANNALS OF THORACIC SURGERY (2021)
Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy
Erin M. Corsini et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2021)
Impact of pathological tumor response after CROSS neoadjuvant chemoradiotherapy followed by surgery on long-term outcome of esophageal cancer: a population-based study
Ali Al-Kaabi et al.
ACTA ONCOLOGICA (2021)
Signet Ring Cell Features are Associated with Poor Response to Neoadjuvant Treatment and Dismal Survival in Patients with High-Grade Esophageal Adenocarcinoma
Daniel Solomon et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Tumor regression grading after neoadjuvant treatment of esophageal and gastroesophageal junction adenocarcinoma: results of an international Delphi consensus survey
G. Saliba et al.
HUMAN PATHOLOGY (2021)
Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial
Ben M. Eyck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancer
Ben M. Eyck et al.
TRIALS (2021)
External Validation of Pretreatment Pathological Tumor Extent in Patients with Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer
Sebastian Brinkmann et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Surgically Managed Signet Ring Cell Esophageal Carcinomas in the National Cancer Database
Tejas S. Sathe et al.
ANNALS OF THORACIC SURGERY (2020)
Signet ring gastric and esophageal adenocarcinomas: characteristics and prognostic implications
Niall Khan et al.
DISEASES OF THE ESOPHAGUS (2020)
Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma
C. Mariette et al.
GASTRIC CANCER (2019)
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran et al.
LANCET (2019)
Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma
Lucas Goense et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS)
Eelke Toxopeus et al.
ANNALS OF SURGICAL ONCOLOGY (2018)
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study
Bo Jan Noordman et al.
LANCET ONCOLOGY (2018)
Cancer of the Esophagus and Esophagogastric Junction: An Eighth Edition Staging Primer
Thomas W. Rice et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survivalThe University of Texas MD Anderson Cancer Center experience
Mariela Blum Murphy et al.
CANCER (2017)
Prognostic Value of Pretreatment Pathological Tumor Extent in Patients Treated With Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal or Junctional Cancer
Joel Shapiro et al.
ANNALS OF SURGERY (2017)
Is Preoperative Chemotherapy Followed by Surgery the Appropriate Treatment for Signet Ring Cell Containing Adenocarcinomas of the Esophagogastric Junction and Stomach?
Ulrike Heger et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Signet Ring Cells in Esophageal Adenocarcinoma Predict Poor Response to Preoperative Chemoradiation
Viren R. Patel et al.
ANNALS OF THORACIC SURGERY (2014)
Signet ring cell adenocarcinomas: Different clinical-pathological characteristics of oesophageal and gastric locations
G. Piessen et al.
EJSO (2014)
Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas - PRODIGE 19 - FFCD1103 - ADCI002
Guillaume Piessen et al.
BMC CANCER (2013)
Preoperative Assessment of Tumor Location and Station-Specific Lymph Node Status in Patients with Adenocarcinoma of the Gastroesophageal Junction
Brechtje A. Grotenhuis et al.
WORLD JOURNAL OF SURGERY (2013)
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation
LR Chirieac et al.
CANCER (2005)
Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma
LR Chirieac et al.
CLINICAL CANCER RESEARCH (2005)